Plus Therapeutics Gains Category III CPT Code X566T for REYOBIQ Delivery
Plus Therapeutics won AMA approval for Category III CPT code X566T to track convection-enhanced delivery of REYOBIQ in recurring glioblastoma and pediatric brain cancer, effective January 1, 2027. The company plans to complete Phase 2 rGBM enrollment and begin Phase 1 pediatric trials in 2026.
1. Approval of CPT Code
The AMA’s CPT Editorial Panel approved Category III CPT code X566T to enable tracking of convection-enhanced delivery for REYOBIQ in recurring glioblastoma and pediatric brain cancer, marking the first code specific to this administration method.
2. Publication and Effective Dates
The new code will be published on July 1, 2026 and becomes effective for clinical reporting on January 1, 2027, allowing standardized data collection and utilization monitoring of REYOBIQ treatments.
3. Clinical Trial Progress
Plus Therapeutics is on track to complete enrollment in its Phase 2 recurrent glioblastoma trial in 2026 and plans to initiate patient enrollment in its Phase 1 pediatric brain cancer trial within the same year.
4. Commercialization and Reimbursement Impact
By establishing a dedicated CPT code, Plus Therapeutics positions REYOBIQ for improved market access, reimbursement negotiations and broader adoption, supporting its path toward commercialization and coverage.